HUTCHMED (China) Limited (HKG:0013)
22.00
-0.24 (-1.08%)
At close: Dec 5, 2025
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $277.68M USD in the half year ending June 30, 2025, a decrease of -47.89%. This brings the company's revenue in the last twelve months to $602.20M, down -1.41% year-over-year. In the year 2024, HUTCHMED (China) had annual revenue of $630.20M, down -24.80%.
Revenue (ttm)
$602.20M
Revenue Growth
-1.41%
P/S Ratio
4.02
Revenue / Employee
$332.52K
Employees
1,811
Market Cap
18.98B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
HUTCHMED (China) News
- 9 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting - GlobeNewsWire
- 4 weeks ago - HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM - Nasdaq
- 4 weeks ago - Hutchmed (HCM) Completes Enrollment for Global Phase III Lung Cancer Study - GuruFocus
- 4 weeks ago - HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 - Slideshow - Seeking Alpha
- 4 weeks ago - HUTCHMED (HCM) Reveals Significant R&D Advancements in Cancer Treatment - GuruFocus
- 4 weeks ago - HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event - GlobeNewsWire
- 5 weeks ago - HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript - Seeking Alpha